At Epic Sciences, we develop clinical solutions that accelerate drug development, and provide valuable insights into the dynamics of cancer growth, evolution and heterogeneity. In fact, Epic Sciences has the world’s leading pipeline of personalized, predictive and proven tests to guide therapy selection across the most impactful drug classes in oncology, including Epic's AR-V7 CTC test — the world’s first predictive liquid biopsy test for metastatic prostate cancer.
No cell left behind™.
Epic was able to achieve these singular advances because we chose a research road less traveled — a bias-free approach that looks at all the cells in a blood sample and thus sees those rare cells that others miss. That insight lead to a proprietary rare-cell detection platform so potent and precise that it can see, identify and characterize all the circulating tumor cells (CTCs) in a sample, and link their response/resistance to a panoply of drug classes. So that doctors can better understand their patient’s cancer and choose with greatest certainty the drug or combination of therapies that will work best.
In addition to spotting one rare cell amid 50 million normal ones, Epic's engine can also see small and apoptotic cells, epithelial to mesenchymal transition cells and CTC clusters. After analyzing individual CTCs for phenotypic and genomic biomarkers, we link single-cell or aggregated subclonal populations to pharmacodynamic data and, most important, to patient outcomes.
The power of seeing in real time.
While analyzing CTCs as a proxy for a patient's entire metastatic burden, we are the only company in the blood-based testing domain that preserves all the white blood cells in the same condition to better understand what the immune system is doing in real time. Thus we can see, simultaneously, what is driving patterns of response to critical drug classes such as PARP inhibitors and Checkpoint inhibitors.
Poised for the future.
Impelled by bias-free research and best-of-class technology, we are well positioned to help companies expedite trials, reduce time-to-market and explore new opportunies. Our technology platform is remakably robust. Thus, although our rare-cell detection platform has primarily been focused on prostate cancer, we're now extending its application into breast, lung and bladder cancer. In fact there's no telling where the science may lead. So we look forward to discussing your present needs, hearing your vision for the future, and helping you get there.